Molecular characterization of the hdm2-p53 interaction

Journal of Molecular Biology

Volumn 269, Issue 5, 1997, Pages 744-756

  Böttger, Angelika ^a   Böttger, Volker ^a   Garcia Echeverria, Carlos ^b   Chène, Patrick ^b   Hochkeppel, Heinz Kurt ^b   Sampson, Wayne ^c   Ang, Kiah ^c   Howard, Stephanie F ^a   Picksley, Steven M ^a   Lane, David P ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b CIBA GEIGY LTD   (Switzerland)

^c Mimotopes Pty Ltd   (Australia)

Author keywords

3G5 epitope; hdm2; Inhibitory peptides; p53; Phage display library

Indexed keywords

DITHIOTHREITOL; N ETHYLMALEIMIDE; PROTEIN P53;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL ONCOGENE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ELECTROPHORETIC MOBILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH DISORDER; HUMAN; MOLECULAR INTERACTION; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0031588025     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1997.1078     Document Type: Article

References (25)

1. Böttger V., Böttger A., Lane E. B., Spruce B. A. Comprehensive epitope analysis of monoclonal anti-proenkephalin antibodies using phage display libraries and synthetic peptides: revelation of antibody fine specificities caused by somatic mutations in the variable region genes. J. Mol. Biol. 247:1995;932-946.
2. Böttger V., Böttger A., Howard S. F., Picksley S. M., Chène P., Garcia-Echeverria C., Hochkeppel H.-K., Lane D. P. Identification of novel mdm2 binding peptides by phage display. Oncogene. 13:1996;2141-2147.
3. Cahilly Snyder L., Yang Feng T., Francke U., George D. L. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat. Cell Mol. Genet. 13:1987;235-244.
4. Chan S., Gabra H., Hill F., Evan G., Sikora K. A novel tumour marker related to the c-myc oncogene product. Mol. Cell. Probes. 1:1987;73-82.
5. Chen J., Marechal V., Levine A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:1993;4107-4114.
6. Chen J., Lin J., Levine A. J. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1:1995;142-152.
7. el Deiry W. S., Kern S. E., Pietenpol J. A., Kinzler K. W., Vogelstein B. Definition of a consensus binding site for p53. Nature Genet. 1:1992;45-49.
8. Hansen S., Hupp T. R., Lane D. P. Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. J. Biol. Chem. 271:1996;3917-3924.
9. Harlow E., Crawford L. V., Pim D. C., Williamson N. M. Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol. 39:1981;861-869.
10. Hupp T. R., Lane D. P. Allosteric activation of latent p53 tetramers. Curr. Biol. 4:1994;865-875.
11. Hupp T. R., Meek D. W., Midgley C. A., Lane D. P. Regulation of the specific DNA binding function of p53. Cell. 71:1992;875-886.
12. Kussie P. H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A. J., Pavletich N. P. Structure of the mdm2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 274:1996;948-953.
13. Leng P., Brown D. R., Shivakumar C. V., Deb S., Deb S. P. N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. Oncogene. 10:1995;1275-1282.
14. Lin J., Chen J., Elenbaas B., Levine A. J. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8:1994;1235-1246.
15. Lu H., Levine A. J. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl Acad. Sci. USA. 92(11):1995;5154-5158.
16. Michalovitz D., Halevy O., Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 62:1990;671-680.
17. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
18. Oliner J. D., Kinzler K. W., Meltzer P. S., George D. L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas [see comments]. Nature. 358:1992;80-83.
19. Oliner J. D., Pietenpol J. A., Thiagalingam S., Gyuris J., Kinzler K. W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362:1993;857-860.
20. Picksley S. M., Vojtesek B., Sparks A., Lane D. P. Immunochemical analysis of the interaction of p53 with MDM2; - fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene. 9:1994;2523-2529.
21. Pinhasi Kimhi O., Michalovitz D., Ben Zeev A., Oren M. Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature. 320:1986;182-184.
22. Stephen C. W., Helminen P., Lane D. P. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J. Mol. Biol. 248:1995;58-78.
23. Thut C. J., Chen J. L., Klemm R., Tjian R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science. 267:1995;100-104.
24. Vojtesek B., Bartek J., Midgley C. A., Lane D. P. An immunochemical analysis of the human nuclear phosphorprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods. 151:1992;237-244.
25. Zauberman A., Barak Y., Ragimov N., Levy N., Oren M. Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53-MDM2 complexes. EMBO J. 12:1993;2799-2808.